Forus's Prescription AI Network Draws $150M, Tripling Its Valuation to $3B

Forus, which describes itself as an AI network for medicine, has raised a $150M Series C led by Bain Capital Ventures, with every existing institutional investor reinvesting. The round triples the company's valuation to $3B, four months after Forus announced a Series B at a $1B valuation in May, and brings total funding to more than $300M, according to CEO and founder Sahir Jaggi.

The company gives every prescription its own AI agent that works like a case manager: it reasons through the patient's clinical, insurance and financial circumstances, then submits forms, places calls, follows up and escalates. The platform is embedded in the workflows practices already use and manages everything between a clinical decision and a patient starting treatment, including insurance authorizations, financial assistance and supply chain coordination. It is free to providers and patients; life sciences companies partner with Forus to integrate their support programs, see where access breaks down, and use the network to develop and launch therapies.

Jaggi said the round came together quickly and was not planned. "We were not looking to raise," he said, adding that Bain Capital Ventures, which has backed Forus since the seed round, approached the company with an offer to lead based on its momentum. The stated challenge is not raising capital but converting it into capacity: "It is in converting that capital into the capacity to support our platform expansion to every doctor's office in the country."

Forus frames the market as high-cost and complex medicines — biologics, specialty drugs and physician-administered therapies — which it says account for the majority of U.S. drug spending and nearly all of the access difficulty. A single specialty prescription can involve up to 15 steps across insurance approvals, financial assistance and fulfillment, and physicians and staff spend about 13 hours a week on prior authorization alone, according to the American Medical Association. Forus says it has double-digit national market share in multiple specialties, supports millions of people across all 50 states, and is used by providers treating patients in 85% of U.S. residential ZIP codes. One Virginia rheumatology clinic reports approvals in under two days and treatment starts within a week or two.

On the commercial side, nine of the top 15 global biopharma companies work with Forus, alongside fast-growing biotechs. Competitively, Jaggi argues most software automates a single step and hands the rest back to the clinic, while Forus consolidates the whole path from prescription to treatment — including faxing insurers that have no electronic prior authorization and calling to confirm the fax arrived.

For the next six months, the company plans to deepen its AI platform with more capable agents and clinical models spanning every drug, condition and payer; expand across all major specialties and care settings, including primary care groups and integrated health systems; and scale its team to meet demand.